Biotechnology, electronics and life science company MOBILion Systems, Inc. announced on Wednesday a collaboration with Dr Oliver Schmitz from the University of Duisburg-Essen, a specialist in analytical chemistry for complex sample analysis.
This partnership highlights MOBILion's commitment to advancing multiomics research through its proprietary SLIM (Structures for Lossless Ion Manipulation) technology.
Dr Schmitz will integrate MOBILion's latest low mass system into his work on complex sample analysis, including Chinese herbal medicine and multidimensional chromatography workflows. The system addresses limitations of traditional LC-MS and ion mobility technologies, enabling precise and efficient metabolomics discovery. Cleaner, more focused data is achieved by reducing overlapping signals, simplifying molecular identification and interpretation.
MOBILion continues to expand its SLIM-based product pipeline, supporting breakthroughs in proteomics, lipidomics, glycomics, and metabolomics. This collaboration builds on the company's recent progress in proteomics applications and commercial platform development.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering